Teva Women’s Health, Inc. and Kinsey Institute at Indiana University Survey Reveals U.S. College Students Need to Study Up on Emergency Contraception

Survey Uncovers Disconnect Between Students’ Contraception Use,
Perceived Risk of Unintended Pregnancy and Knowledge about
Over-the-Counter Emergency Contraception

FRAZER, Pa.–(BUSINESS WIRE)–Teva Women’s Health, Inc., the maker of Plan B One-Step®
(levonorgestrel) 1.5 mg tablet, announced today results of the
first-ever “EC IQ” survey of 3,600 female and male undergraduate and
graduate students in the United States. The Teva-sponsored survey was
developed and conducted by research scientists at the Kinsey Institute,
Indiana University, an institution focused on sexuality, gender and
reproduction research. The survey assessed students’ contraception use
and attitudes about unintended pregnancy, and revealed what demographic
and lifestyle factors may contribute to their level of knowledge about
over-the-counter (OTC) emergency contraception (EC), or their “EC IQ.”

The survey revealed 64 percent of 2,638 sexually active college students
surveyed are using contraception inconsistently, yet only 15 percent of
students sampled believe they are at high risk of an unintended
pregnancy. This disconnect between contraception use and perceived risk
is particularly noteworthy, given prior research shows 45 percent of all
pregnancies in the U.S. are unintended (unwanted or mistimed) and 41
percent of those pregnancies are due to inconsistent use of
contraception. In the survey, 69 percent of students revealed an
unintended pregnancy would be highly disruptive to their lives, though
many did not know some of the most basic facts about OTC EC, which helps
prevent pregnancy when used as directed after unprotected sex or birth
control failure. OTC EC should not be used as regular birth control
because it is not as effective.

“With the unintended pregnancy rate in the U.S. remaining high and
college students reporting having sex without consistent, regular
contraception use, it’s important they know how OTC EC works and where
to get it if they need it,” said Dr. Justin Garcia, lead researcher for
the survey and renowned expert in sexual health at the Kinsey Institute,
Indiana University. “These survey findings clearly illustrate the need
for more open and honest discussion about reproductive health,
contraception, and OTC EC.”

In the survey, EC IQ was assessed by asking 3,600 respondents a series
of 12 questions on OTC EC, including what is required to purchase it in
the U.S., how it works, what it is and what it is not. The survey
revealed many were not well informed about OTC EC, specifically:

  • 62 percent of students falsely believed there was an age restriction
    to purchase OTC EC.
  • 53 percent were unaware an I.D. is not necessary to purchase OTC EC.
    In fact, OTC EC has been available in the U.S. without an age
    restriction or I.D. requirement since 2013.
  • 57 percent of students were not aware OTC EC should be taken up to 72
    hours (three days) following unprotected sex or birth control failure.
    The sooner it’s taken, the better it works.

After evaluating what students know about OTC EC, the survey assessed a
range of lifestyle and demographic factors to investigate what may
contribute to a lower or higher EC IQ. On average, the survey found
students with a higher EC IQ include: women, students who think about
sex often, students in committed dating relationships, students who
attend private colleges, and students who identify as night owls.
Conversely, students with a lower EC IQ include: men, students who have
had more sexual partners in the last year, students who frequently use
dating apps, students who attend single-sex colleges, and students who
play varsity sports.

“At Teva Women’s Health, we are committed to educating women, and men,
including college students, about their contraception options so they
feel empowered to make informed decisions about their reproductive
health,” said Deb Macaleer, Vice President and General Manager of Teva
Women’s Health. “Working with a leading institution like the Kinsey
Institute to uncover what college students know about OTC EC is a
significant step in addressing education gaps to provide students with
accurate information.”

About Plan B One-Step®

Plan B One-Step® (levonorgestrel) 1.5 mg tablet is a
progestin-only emergency contraceptive that helps prevent pregnancy when
taken within 72 hours (3 days) after birth control failure or
unprotected sex. The sooner it’s taken, the better it works. Plan B
One-Step® works mainly by stopping the release of an egg from
the ovary. It is possible that Plan B One-Step® may
also work by preventing fertilization of an egg (the uniting of sperm
with the egg) or by preventing attachment (implantation) to the uterus
(womb). When used as directed, about 7 out of every 8 women who would
have gotten pregnant will not become pregnant after taking
Plan B One-Step®. Plan B One-Step® is
not an abortion pill; it will not work if a woman is already pregnant
and will not affect an existing pregnancy. Plan B One-Step®
is a back-up method of preventing pregnancy, and should not be used as
regular birth control because it is not as effective. Side effects may
include menstrual changes, nausea, lower stomach (abdominal) pain,
tiredness, headache, dizziness, breast pain, and vomiting. Plan B
One-Step® does not protect a woman against HIV/AIDS or
sexually transmitted diseases (STDs). For additional information, visit
or call the Plan B One-Step® Information Center at

About Teva

Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical
company that delivers high-quality, patient-centric healthcare solutions
used by millions of patients every day. Headquartered in Israel, Teva is
the world’s largest generic medicines producer, leveraging its portfolio
of more than 1,800 molecules to produce a wide range of generic products
in nearly every therapeutic area. In specialty medicines, Teva has a
world-leading position in innovative treatments for disorders of the
central nervous system, including pain, as well as a strong portfolio of
respiratory products. Teva integrates its generics and specialty
capabilities in its global research and development division to create
new ways of addressing unmet patient needs by combining drug development
capabilities with devices, services and technologies. Teva’s net
revenues in 2015 were $19.7 billion. For more information, visit

Teva’s Safe Harbor Statement under the U. S. Private Securities
Litigation Reform Act of 1995:

This release contains forward-looking statements, which are based on
management’s current beliefs and expectations and involve a number of
known and unknown risks and uncertainties that could cause our future
results, performance or achievements to differ significantly from the
results, performance or achievements expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: our ability to
develop and commercialize additional pharmaceutical products;
competition for our specialty products, especially Copaxone® (which
faces competition from orally-administered alternatives and a generic
version); our ability to integrate Allergan plc’s worldwide generic
pharmaceuticals business (“Actavis Generics”) and to realize the
anticipated benefits of the acquisition (and the timing of realizing
such benefits); the fact that following the consummation of the Actavis
Generics acquisition, we are dependent to a much larger extent than
previously on our generic pharmaceutical business; potential
restrictions on our ability to engage in additional transactions or
incur additional indebtedness as a result of the substantial amount of
debt incurred to finance the Actavis Generics acquisition; the fact that
for a period of time following the Actavis Generics acquisition, we will
have significantly less cash on hand than previously, which could
adversely affect our ability to grow; the possibility of material fines,
penalties and other sanctions and other adverse consequences arising out
of our ongoing FCPA investigations and related matters; our ability to
achieve expected results from investments in our pipeline of specialty
and other products; our ability to identify and successfully bid for
suitable acquisition targets or licensing opportunities, or to
consummate and integrate acquisitions; the extent to which any
manufacturing or quality control problems damage our reputation for
quality production and require costly remediation; increased government
scrutiny in both the U.S. and Europe of our patent settlement
agreements; our exposure to currency fluctuations and restrictions as
well as credit risks; the effectiveness of our patents, confidentiality
agreements and other measures to protect the intellectual property
rights of our specialty medicines; the effects of reforms in healthcare
regulation and pharmaceutical pricing, reimbursement and coverage;
competition for our generic products, both from other pharmaceutical
companies and as a result of increased governmental pricing pressures;
governmental investigations into sales and marketing practices,
particularly for our specialty pharmaceutical products; adverse effects
of political or economic instability, major hostilities or acts of
terrorism on our significant worldwide operations; interruptions in our
supply chain or problems with internal or third-party information
technology systems that adversely affect our complex manufacturing
processes; significant disruptions of our information technology systems
or breaches of our data security; competition for our specialty
pharmaceutical businesses from companies with greater resources and
capabilities; the impact of continuing consolidation of our distributors
and customers; decreased opportunities to obtain U.S. market exclusivity
for significant new generic products; potential liability in the U.S.,
Europe and other markets for sales of generic products prior to a final
resolution of outstanding patent litigation; our potential exposure to
product liability claims that are not covered by insurance; any failure
to recruit or retain key personnel, or to attract additional executive
and managerial talent; any failures to comply with complex Medicare and
Medicaid reporting and payment obligations; significant impairment
charges relating to intangible assets, goodwill and property, plant and
equipment; the effects of increased leverage and our resulting reliance
on access to the capital markets; potentially significant increases in
tax liabilities; the effect on our overall effective tax rate of the
termination or expiration of governmental programs or tax benefits, or
of a change in our business; variations in patent laws that may
adversely affect our ability to manufacture our products in the most
efficient manner; environmental risks; and other factors that are
discussed in our Annual Report on Form 20-F for the year ended December
31, 2015 and in our other filings with the U.S. Securities and Exchange
Commission (the “SEC”). Forward-looking statements speak only as of the
date on which they are made and we assume no obligation to update or
revise any forward-looking statements or other information, whether as a
result of new information, future events or otherwise.


Teva Women’s Health, Inc.
United States
, 215-591-8974
Nancy Leone, 215-284-0213
, 610-786-7335